New Mexico
Register / Volume XXXVII, Issue 22 / November 17, 2026
This is an amendment to
16.19.4 NMAC, Section 16 effective 11/17/2026
16.19.4.16 RESPONSIBILITIES
OF PHARMACIST AND PHARMACIST INTERN:
A. The following responsibilities
require the use of professional judgment and therefore shall be performed only
by a pharmacist or pharmacist intern:
(1) receipt of all new verbal prescription orders and reduction
to writing;
(2) initial identification, evaluation and interpretation of
the prescription order and any necessary clinical clarification prior to dispensing;
(3) professional consultation with a patient or his agent
regarding a prescription;
(4) evaluation of available clinical data in patient medication
record system;
(5) oral communication with
the patient or patient's agent of information, as defined in this section under
patient counseling, in order to improve therapy by ensuring proper use of drugs
and devices;
(6) professional consultation with the prescriber, the
prescriber's agent, or any other health care professional or authorized agent
regarding a patient and any medical information pertaining to the prescription;
(7) drug regimen review, as defined in Section 61-11-2L NMSA
1978;
(8) professional consultation, without dispensing, will require
that the patient be provided with the identification of the pharmacist or
pharmacy intern providing the service.
B. Only
a pharmacist shall perform the following duties:
(1) final check on all aspects of the completed prescription
including sterile products and cytotoxic preparations, and assumption of the
responsibility for the filled prescription, including, but not limited to,
appropriateness of dose, accuracy of drug, strength, labeling, verification of
ingredients and proper container; except that the pharmacist's final check
need not include physically opening the container to re-confirm the drug,
strength, and dosage form where those attributes have been confirmed either (i)
by a certified pharmacy technician through technology-assisted product
verification under 16.19.22.8 NMAC, or (ii) by an automated filling system for
which the pharmacist verification requirements are deemed satisfied under
Subsection D of 16.19.6.28 NMAC; in either case the pharmacist remains
responsible for the final check and for the filled prescription;
(2) evaluation of pharmaceuticals for formulary selection
within the facility;
(3) supervision of all supportive personnel activities
including preparation, mixing, assembling, packaging, labeling and storage of
medications;
(4) ensure that supportive personnel have been properly trained
for the duties they may perform;
(5) any verbal communication with a patient or patient's
representative regarding a change in drug therapy or performing therapeutic
interchanges (i.e. drugs with similar effects in specific therapeutic
categories); this does not apply to substitution of generic equivalents;
(6) any other duty required of a pharmacist by any federal or
state law.
C. Patient
records.
(1) A reasonable effort must be made to obtain, record and
maintain at least the following information:
(a) name, address, telephone number, date
of birth (or age) and gender of the patient;
(b) individual medical history, if
significant, including disease state or states, known allergies and drug
reactions and a comprehensive list of medications and relevant devices; and
(c) pharmacist’s comments relevant to the
individuals drug therapy.
(2) Such information contained in the patient record should be
considered by the pharmacist or pharmacist intern in the exercise of their
professional judgment concerning both the offer to counsel and the content of
counseling.
D. Prospective
drug regimen review.
(1) Prior to dispensing any prescription, a pharmacist shall
review the patient profile for the purpose of identifying:
(a) clinical abuse/misuse;
(b) therapeutic duplication;
(c) drug-disease contraindications;
(d) drug-drug interactions;
(e) incorrect drug dosage;
(f) incorrect duration of drug treatment;
(g) drug-allergy interactions;
(h) appropriate medication indication.
(2) Upon recognizing any of the above, a pharmacist, using
professional judgment, shall take appropriate steps to avoid or resolve the
potential problem. These steps may
include requesting and reviewing a controlled substance prescription monitoring
report or another states’ reports if applicable and available, and consulting
with the prescriber and counseling the patient.
The pharmacist shall document steps taken to resolve the potential
problem.
E. Prescription
monitoring program (PMP) report for opioid prescriptions. When presented with an opioid prescription
for a patient, obtaining and reviewing a PMP report for that patient can be an
important tool that assists the pharmacist in identifying issues or problems
that put his or her patient at risk of prescription drug abuse, overdose, or
diversion. A pharmacist shall use
professional judgment based on prevailing standards of practice in determining
whether to obtain and review a PMP report before dispensing an opioid
prescription to that patient, and shall document his or her action regarding
such reports.
(1) A pharmacist shall request and review a PMP report covering
at least a one year time period and another states’ report, where applicable
and available if;
(a) a pharmacist becomes aware of a person
currently exhibiting potential abuse or misuse of opioids (i.e.
over-utilization, early refills, multiple prescribers, appears sedated or
intoxicated upon presenting a prescription for an opioid or an unfamiliar patient
requesting an opioid by specific name, street name, color, or identifying
marks, or paying cash when the patient has prescription insurance);
(b) a pharmacist receives an opioid
prescription issued by a prescriber with whom the pharmacist is unfamiliar
(i.e. prescriber is located out-of-state or prescriber is outside the usual
pharmacy geographic prescriber care area);
(c) a pharmacist receives an opioid
prescription for an unfamiliar patient who resides outside the usual pharmacy
geographic patient population area;
(d) a pharmacist receives an initial
prescription for any long-acting opioid formulations, including oral and
transdermal dosage forms (e.g fentanyl or methadone);
(e) a pharmacist becomes aware of a
patient receiving an opioid concurrently with a benzodiazepine or carisoprodol;
(2) The pharmacist shall document the review of these PMP
reports.
(3) Upon recognizing any of the above conditions described in
Paragraph (1 ) of Subsection E of 16.19.4.16 NMAC, a pharmacist, using
professional judgment, shall take appropriate steps to avoid or resolve the
potential problem. These steps may
include consulting with the prescriber and counseling the patient. The pharmacist shall document steps taken to
resolve the potential problem.
(4) After obtaining an initial PMP report on a patient, a
pharmacist shall use professional judgment based on prevailing standards of
practice, in deciding the frequency of requesting and reviewing further
prescription monitoring reports and other states’ reports for that
patient. Except that PMP reports shall
be reviewed a minimum of once every three months during the continuous use of
opioids for each established patient.
The pharmacist shall document the review of these reports.
(5) In the event a report is not immediately available, the
pharmacist shall use professional judgment in determining whether it is
appropriate and in the patient’s best interest to
dispense the prescription prior to receiving a report.
(6) A prescription for an opioid written for a patient in a
long term care facility (LTCF) or for a patient with a medical diagnosis
documenting a terminal illness is exempt from Subsection E of 16.19.4.16
NMAC. If there is any question whether a
patient may be classified as having a terminal illness, the pharmacist shall
contact the practitioner. The pharmacist
shall document whether the patient is “terminally ill” or an “LTCF patient”.
F. Counseling.
(1) Upon receipt of a new prescription drug order and following
a review of the patient's record, a pharmacist or pharmacist intern shall
personally offer to counsel on matters which will enhance or optimize drug
therapy with each patient or the patient's agent. Upon receipt of a refill prescription drug
order a pharmacy technician may query the patient or patient's agent regarding
counseling by the pharmacist or pharmacist intern concerning drug therapy. Such counseling shall be in person, whenever
practicable, or by telephone, and shall include appropriate elements of patient
counseling which may include, in their professional judgment, one or more of
the following:
(a) the name and description of the drug;
(b) the dosage form, dosage, route of
administration, and duration of drug therapy;
(c) intended use of the drug and expected
action;
(d) special directions and precautions for
preparation, administration and use by the patient;
(e) common severe side or adverse effects
or interactions and therapeutic contraindications that may be encountered,
including their avoidance and the action required if they occur;
(f) techniques for self-monitoring drug
therapy;
(g) proper storage;
(h) prescription’s refill information;
(i) action to be taken in the event of a
missed dose;
(j) the need to check with the pharmacist
or practitioner before taking other medication; and
(k) pharmacist comments relevant to the
individual's drug therapy, including any other information peculiar to the
specific patient or drug.
(2) [REPEALED]
(3) Alternative forms of patient information may be used to
supplement patient counseling when appropriate.
Examples include, but not limited to, written information leaflets,
pictogram labels and video programs.
(4) Patient counseling, as described above and defined in this
regulation shall not be required for in-patients of a hospital or institution
where other licensed health care professionals are authorized to administer the
drug(s).
(5) A pharmacist shall in no way attempt to circumvent or
willfully discourage a patient or patient's agent from receiving
counseling. However, a pharmacist shall
not be required to counsel a patient or patient's agent when the patient or
patient's agent refuses such consultation.
(6) When the patient or agent is not present when the
prescription is dispensed including, but not limited to, a prescription that
was shipped by the mail, the pharmacist shall ensure that the patient receives
written notice of available counseling.
Such notice shall include days and hours of availability, and: (a) of his or
her right to request counseling; and (b) a toll-free telephone number in which
the patient or patient's agent may obtain oral counseling from a pharmacist who
has ready access to the patient's record.
For pharmacies delivering more than fifty percent of their prescriptions
by mail or other common carrier, the hours of availability shall be a minimum
of 60 hours per week and not less than six days per week. The facility must have sufficient toll-free
phone lines and personnel to provide counseling within 15 minutes.
(7) In every pharmacy there shall be prominently posted in a
place conspicuous to and readable by prescription drug consumers a notice
concerning available counseling.
G. [REPEALED]
H. Regulatory assessment. Profiles, either electronic or hard copy,
shall be available for inspection, and shall provide the capability of storing
the described historical information.
The profiles must demonstrate that an effort is being made to fulfill
the requirements by the completion of the detail required. A patient record shall be maintained for a
period of not less than three years from the date of the last entry in the
profile record.
[8/27/1990; 16.19.4.16 NMAC -
Rn, 16 NMAC 19.4.16, 3/30/2002; 16.19.4.16 NMAC - Rn, 16.19.4.17 NMAC,
12/15/2002; A, 2/1/2004; A, 11/30/2004; A, 1/15/2005; A, 1/31/2007; A,
8/31/2012; A, 10/25/2012; A, 10/19/2019; A, 9/13/2022; A, 05/07/2024; A,
11/17/2026]